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Abstract 
            Leukocyte recruitment is critical during many acute and chronic inflammatory 
diseases. Chemokines are key mediators of leukocyte recruitment during the inflammatory 
response, by signaling through specific chemokine G-protein coupled receptors (GPCRs). In 
addition, chemokines interact with cell surface glycosaminoglycans (GAGs) to generate a 
chemotactic gradient. The chemokine IL8/CXCL8, a prototypical neutrophil chemoattractant, 
is characterised by a long, highly positively charged GAG-binding C-terminal region, absent 
in most other chemokines. In order to examine whether the CXCL8 C-terminal peptide has a 
modulatory role in GAG binding during neutrophil recruitment, we synthesised the wild type 
CXCL8 C-terminal [CXCL8 (54-72)] (Peptide 1), a peptide with a substitution of glutamic 
acid (E) 70 with lysine (K) (Peptide 2) to increase positive charge; and also, a scrambled 
sequence peptide (Peptide 3). Surface Plasmon Resonance showed that Peptide 1, 
corresponding to the core CXCL8 GAG-binding region, binds to GAG but Peptide 2 binding 
was detected at lower concentrations. In the absence of cellular GAG, the peptides did not 
affect CXCL8 induced calcium signaling or neutrophil chemotaxis along a diffusion gradient, 
suggesting no effect on GPCR binding. All peptides equally inhibited neutrophil adhesion to 
endothelial cells under physiological flow conditions. Peptide 2, with its greater positive 
charge and binding to polyanionic GAG, inhibited CXCL8-induced neutrophil 
transendothelial migration. Our studies suggest that the E70K CXCL8 peptide, may serve as 
a lead molecule for further development of therapeutic inhibitors of neutrophil-mediated 
inflammation based on modulation of chemokine-GAG binding. 
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Introduction 
           Leukocyte recruitment, a hallmark of the inflammatory response, is a crucial 
component of many acute and chronic inflammatory situations 1-3. Chemokines are small, 
soluble chemotactic proteins that co-ordinate leukocyte recruitment 4. They can be expressed 
in response to pro-inflammatory mediators such as the cytokines TNF, IFN-γ or IL-1β. 
Chemokines recruit leukocytes to a site of injury, by binding to the endothelium via 
glycosaminoglycans (GAGs), forming a chemokine gradient and activating integrins which 
allow leukocyte adhesion. In addition, chemokines are involved in many other processes such 
as angiogenesis, proliferation, development, and the control of leukocyte mobilization from 
primary or secondary lymphoid organs 5-9. Chemokine function depends, amongst many other 
factors, on their signaling via specific chemokine G-protein coupled receptors (GPCRs). The 
interaction between a chemokine and its receptor is an attractive therapeutic target in many 
diseases including rheumatoid arthritis 10-12, psoriasis 13 or acute and chronic organ damage 
after ischaemia reperfusion injury (IRI) following transplantation 14, 15.  
            Studies that have focused on the chemokine interaction with GPCRs have led to the 
development of several neutralising antibodies, modified chemokines and antagonists 16-21. 
However, to date, only two chemokine receptor antagonists have been fully validated and 
marketed as therapeutics, Maraviroc (a CCR5 antagonist) and AMD3100 (a CXCR4 
antagonist) 22-24. These two antagonists are not used as anti-inflammatory drugs, but rather as 
a Human Immunodeficiency Virus (HIV) entry inhibitor, and as a hematopoietic stem cell 
mobiliser during transplantation, respectively. The challenge of targeting chemokines in anti-
inflammatory therapy arises primarily from the apparent redundancy within the human 
chemokine system 25, 26.  
In addition to the well-characterised, high affinity interaction of chemokines with 
their specific GPCRs, chemokine activity in vivo also depends on their interaction with 
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glycosaminoglycans (GAGs), such as endothelial heparan sulphate (HS) 21, 27. GAGs are 
ubiquitously present on cell surfaces and in the extracellular matrix (ECM). They are thought 
to inhibit chemokine diffusion, recruiting chemokines at high concentration forming a 
gradient towards the site of injury 28-30. The highly sulphated and acidic GAGs bind to basic 
residues within chemokines largely through electrostatic forces, but also through Van der 
Waals interactions and hydrogen bonding. This usually involves residues such as arginine, 
lysine or histidine, which typically form the BBXB or (B)BXX(X/B)BXXB(B) peptide 
sequence signature, where B is a basic amino acid residue and X a non-conserved amino acid, 
which is present in virtually all chemokines 27. The importance of the chemokine-GAG 
interaction is highlighted by studies that have selectively targeted either GAG or GPCR 
binding domains. For example, chemokines with increased GAG binding but decreased 
GPCR binding, show anti-inflammatory activity in in vivo models of CXCL8/neutrophil-
driven inflammation presumably by disrupting the natural chemokine gradient 31. 
CXCL8 levels significantly increase during the inflammatory response associated 
with IRI 32, 33, which can lead to acute kidney injury (AKI) 34, 35 and transplant rejection 36-38. 
CXCL8 expressed at high concentrations on the endothelial GAG surface at the site of injury, 
contributes to neutrophil firm arrest, by activation of integrins 39. Therefore, modulation of 
CXCL8 haptotactic gradient might have potential in ameliorating the IR injury and therefore 
improve organ function 30, 32, 34. Therapeutic targeting of CXCL8 and its association with HS 
has been investigated in numerous neutrophil driven inflammatory diseases such as chronic 
obstructive pulmonary disease (COPD), Crohn’s disease and psoriasis 40. A CXCL8-based 
decoy protein named PA401, with decreased GPCR binding and increased GAG binding, 
decreased CXCL8-mediated neutrophil recruitment in in vivo studies, suggesting its 
translational potential for the treatment of respiratory diseases such as COPD or cystic 
fibrosis 41.  
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The C-terminal alpha-helical region of CXCL8 is known to be critical for GAG 
binding (Figure 1), largely due to its positive electrostatic charge giving it micromolar affinity 
for negatively charged GAGs 29, 42-44. This binding is mediated by core residues H18, K20, 
R60, K64, K67 and R68, as shown in Figure 1 where known CXCL8-receptor binding 
residues are also highlighted. 
In this study, we aimed to assess whether the CXCL8 C-terminal peptide (54-72) 
could modulate CXCL8 function. We synthesised the CXCL8 wild type C-terminal region 
(54-72) (WT peptide, Peptide 1), a peptide with substitution of glutamic acid (E) 70 with 
lysine (K), in order to increase the peptide positive charge thus its GAG binding potential 
(Peptide 2), and a scrambled peptide containing the wild type amino acids (Peptide 3) (Figure 
1). The biophysical properties of the peptides and their potential biological functions, using in 
vitro cytokine-mediated neutrophil flow-based adhesion and transendothelial migration 
studies, were investigated. 
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Materials & Methods  
Human Neutrophil Isolation 
            Primary neutrophils (PMN) were isolated from whole blood of healthy volunteers. 
Ethical approval to obtain blood from healthy volunteers was granted by the County Durham 
and Tees Valley Research Ethics Committee (12/NE/0121). Primary neutrophils were isolated 
by dextran sedimentation (Dextran T500, Pharmacosmos, Holbaek, Denmark) and 
centrifugation on Percoll (GE Healthcare, Buckinghamshire, UK) density gradients as 
previously described 45.  
 
Synthesis of chemokine peptides 
            The chemokine C-terminal peptides (Peptides 1-3) were synthesised on Rink Amide 
resin using Fmoc Solid-Phase Peptide Synthesis (SPPS) on a CEM Liberty 1 single-channel 
microwave peptide synthesizer equipped with a Discover microwave unit, as earlier described 
46. After synthesis, peptides were acetylated at the N-terminal (20% acetic anhydride), having 
amide at the C-terminal. They were then cleaved from the resin, and crude peptides were 
purified by semi-prep Reverse-Phase High Performance Liquid Chromatography (RP-
HPLC). Then peptides were characterised by matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) using an Autoflex II ToF/ToF mass spectrometer (Bruker Daltonik 
GmBH, Germany), and using the Pep-Calc calculator to analyse the sequence 47 and the 
obtained MS spectra. Following analytical RP-HPLC examined the pure peptide. Chemokine 
peptides were initially synthesised at Durham University Chemistry Department UK, and 
further synthesised by ISCA Biochemicals, UK (>95% purity). 
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Circular Dichroism Spectroscopy 
            Far-UV circular dichroism (CD) spectroscopy was conducted using a Jasco J-810 
spectropolarimeter (Jasco, GmbH, Germany) in the range of (240-197) nm wavelength, with 
a 1mm path length and a 500 µL quartz cuvette. Peptide samples (Peptide 1, Peptide 2 or 
Peptide 3) were diluted (5-100) µM in a phosphate buffered solution (PBS). 300 µL peptide 
solution was transferred to a cuvette for the measurements. All data collection was taken at 
room temperature, and the mean spectrum derived from 5-10 scans was corrected by 
subtraction of the buffer blank, as previously reported 48. For samples of peptide combined 
with heparin (Sigma-Aldrich, St Louis, MO, USA), spectrum was also corrected by 
subtraction of heparin blank. Scans were conducted at 50 nm/min, 1 nm data pitch, 5 mdeg 
sensitivity and a 2s response 49. 
 
Surface Plasmon Resonance 
            Surface plasmon resonance was performed using a BIAcore X100 as previously 
described 50. The running buffer used was HBS-P (10mM HEPES pH7.4, 150mM NaCl, 
0.005% Tween 20). Unless otherwise stated all reagents were from GE Healthcare (Uppsala, 
Sweden). To allow immobilisation onto the streptavidin-coated chip, biotinylated GAG 
heparin was obtained as previously described 50-52 (generously provided by Prof Hughes 
Lortat-Jacob’s Laboratory, Institute of Structural Biology, Grenoble, France). Mono-
biotinylation at the reducing end of the GAG is important for correct presentation when 
immobilised. 5-20µg/ml biotinylated heparin in 300mM NaCl were injected at 10µl/min for 
30sec followed by a 2M NaCl wash to remove unbound heparin. Injections were repeated 
until a total RU of 200 was achieved. Following preparation of the chip surface, SPR assays 
assessed the GAG binding properties of CXCL8; and synthesised peptides (Peptide 1, Peptide 
2, and Peptide 3). A range of CXCL8 concentrations (50-1000) nM (CN-09) (Almac, 
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Edinburgh, UK) were flowed across the chip at 5µl/min for 5mins followed by a 500sec 
dissociation phase and their resonance units (RU) were measured. Same conditions were 
applied to the peptides analysed at concentrations (2500nM - 10000µM). After every 
chemokine or chemokine peptide measurement, regeneration buffer was used to remove 
sample from the chip surface (10mM HEPES, 2M NaCl, 50mM EDTA, 0.005% Tween 20). 
Binding was calculated by subtraction of the RU of the SA flow cell from the RU of the 
GAG-SA flow cell. Data analysis was performed using BIAevaluation 4.1. 
 
Solute diffusion gradient chemotaxis and transendothelial chemotaxis of neutrophils 
            Chemotaxis experiments were done using a Transwell system (BD Falcon, USA), as 
previously reported 53. First 24 well companion plates (BD Falcon, USA) were blocked with 
1ml 1% BSA/RPMI (Sigma-Aldrich, St Louis, MO, USA) (Lonza, Wokingham, UK) per 
well for 1hour before the assay to prevent chemokine binding and consequent decreased 
chemokine concentration. Then, 800µL of 10nM chemokine, after optimization (data not 
shown) and as earlier described 54-56, or chemokine peptide at range of (0.1-10000) nM in 1% 
BSA/RPMI were added to each well. 3µm-pore size cell culture inserts (BD Falcon, USA) 
formed the transwell upper chamber where 500µL of 3x105 PMN in 1% BSA/RPMI were 
added. Wells containing 1% BSA/RPMI only on the transwell bottom chamber were used as 
a negative control. Plate was then incubated at 37°C for 90 minutes. After incubation, cells 
that had fully migrated to the transwell lower chamber were counted by flow cytometry as a 
ratio to known number of counting beads. For transendothelial chemotaxis, three days before 
the assay Human Microvascular Endothelial Cells (HMECs) (ATCC CRL-3243) 57, 58 were 
seeded onto the transwell upper chamber using 500µL of 2x105 HMECs per insert in MCDB-
131 media (10372019) (Thermo Fisher, Waltham, MA, USA) with 10% FBS as earlier 
described 59, 60. MCDB-131 media was then carefully aspirated before the assay. Anti-ICAM-
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1 blocking monoclonal antibody (HA58) (eBioscience; Thermo Fisher, Waltham, MA, USA) 
and IgG1 κ isotype control (MOPC-21) (BD Biosciences, San Jose, CA, USA) were used to 
treat the HMEC layer at 20µg/mL in 0.5% BSA/PBS for 30 mins at room temperature. 
 
Calcium signaling 
            Intracellular calcium (Ca2+) was measured loading cells with Indo-1, AM. For each 
tube, three million neutrophils were used. Freshly isolated neutrophils were first left to rest in 
incubator for about 15 minutes, and then used for the experiment. Cells were washed in 
HBSS (Sigma-Aldrich, St Louis, MO, USA) and resuspended at 10 million cells per mL. 
Then, cells were washed in HBSS supplemented with 1mM CaCl2, 1mM MgCl2, 1% FBS 
(v/v). Once cells were washed, they were loaded with 3M indo-1, AM, and incubated for 30 
minutes at 37C covered in foil. After the 30 minutes of indo-1, AM incubation, cells were 
washed with supplemented HBSS at 400xg for 5 minutes, then resuspended at 3 million cells 
per 1.5mL in their corresponding FACS tube and left to rest for 30 minutes at 37C before 
analysis. Calcium flux was measured by FACS-Fortessa flow cytometry, using UV filter 
530/30. Once settings were adjusted with unstained cells at low flow rate, the stained cells 
were run. As baseline, stained untreated cells (HBSS only) were first run for 1 minute at 
medium flow. Then 1L HBSS or chemokine was added for 4 minutes, and then 8L 
ionomycin (I0634) (Sigma-Aldrich, St Louis, MO, USA) were added for 2 minutes. Cells 
were studied for the effect of CXCL8 on calcium flux and compared to the effect of CXCL8 
combined with Peptide 1, Peptide 2, or Peptide 3. Calculation of intracellular calcium 
concentrations, measured in terms of the light emission as a ratio of fluorescence intensities 
at 340 nm and 380 nm, was done using the equation [calcium (nmol/L)] = Kd x (R - Rmin) / 
(Rmax - R), where Kd (844 nmol/L) is the dissociation constant of calcium bound to the 
fluorochrome 61 and R is the peak intracellular calcium flux in response to the additive 
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(chemokine or chemokine peptide). The basal concentration (HBSS, negative control) was 
subtracted to calculate the values. 
 
Flow-based neutrophil adhesion  
            In order to evaluate the neutrophil adhesion in response to chemokine or chemokine 
peptide under physiological in vitro conditions, the Venaflux platform (Cellix Ltd., Dublin, 
Ireland) was used, similarly to previous studies 62-64. To accommodate an endothelial layer on 
the biochip platform for neutrophil perfusion, Vena8 Endothelial+ chip was initially coated 
with 10µL 100µg/mL fibronectin (Sigma-Aldrich, St Louis, MO, USA). Coated biochip was 
stored in a closed humidified chamber O/N at 4C. On the first day, Human Umbilical Vein 
Endothelial Cells (HUVECs) (C-12203) (PromoCell, Heidelberg, Germany) were treated on 
75cm2 flask with 1 ng/mL TNF (210-TA-010) (R&D Systems, MN, USA) O/N at 37C 65. 
Next day, fibronectin-coated Vena8 Endo+ biochip was seeded with 10µL of 1.5million 
HUVECs per 100L, used as negative control, or with TNF-stimulated HUVECs, as positive 
control. HUVEC layer was generated within 1-1.5 hour of seeding. For it, addition of 40µL 
of extra culture media to each channel reservoir was required 10-15 minutes right after 
HUVEC seeding to humidify channel and generate the endothelial layer. Afterwards, 
chemokine treatment was done. Seeded biochip channel was treated with chemokine (20nM), 
chemokine peptide (50nM) (Peptide 1, Peptide 2 or Peptide 3); or Low Molecular Weight 
Heparin (LMWH) tinzaparin (50nM) (Leo Pharmaceuticals, Ballerup, Denmark) to analyse 
their potential role in displacing the chemokine from GAG 66. In parallel, different CXCR1/2 
antagonists (CXCR1/2 antagonists repertaxin (Cayman Chemical, Cambridge, UK) and 
SB225002 (SML0716) (Sigma-Aldrich, St Louis, MO, USA)); and CXCR2 antagonist 
SB265610 (SML0421) (Sigma-Aldrich, St Louis, MO, USA) at 50nM, to analyse their role in 
displacing the chemokine from GPCR 67, were used to treat neutrophils before the assay. 
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10L treatment were inserted into each channel, followed by careful addition of 40L 
treatment on to each channel reservoir. Effect of each treatment on the neutrophil flow-based 
adhesion was evaluated using the Venaflux platform. 3x105 primary neutrophils were flowed 
per mL through each biochip channel and analysed. Cell adhesion analysis was done using 
ImageJ Analysis Software. Cell adhesion count for each treatment was calculated from the 
average of five standard fields of view (FOV) of adhered neutrophils.  
 
Data analysis 
            Data were analysed using Prism7c software (GraphPad Software Inc, La Jolla, CA, 
USA). Each graph column denotes mean (M) and each bar indicates standard error of the 
mean (SEM). P values were calculated using one-way statistical analysis of variance 
(ANOVA) followed by Bonferroni’s post hoc test, with significant differences when p<0.05 
(*), highly significant when p<0.01 (**), and extremely significant when p<0.001 (***) or 
p<0.0001 (****). 
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Results 
Design, Synthesis and Biophysical Characterisation of CXCL8 C-Terminal Peptide 
            The wild-type C-terminal region of CXCL8 [CXCL8 (54-72)] (Peptide 1), the E70K 
peptide (Peptide 2), and a scrambled peptide with the same amino acids as the wild type 
peptide in a random order, (Peptide 3), were synthesised using Fmoc-SPPS on Rink Amide 
resin (Figure S1). The purified peptides were characterised by MALDI-TOF and analytical 
RP-HPLC. A summary of yields and purity for the three peptides is shown in Table 1. 
Circular Dichroism (CD) was used to determine the structure of synthesised peptides alone 
and in comparison with peptides combined with heparin. All peptides showed an extended, 
non-helical or random coil structure, different to the α–helix structure of this region within 
full-length CXCL8. However, Peptide 1 and Peptide 2 in solution with heparin showed a 
minor change in structure, not seen with Peptide 3, indicating a potential interaction between 
CXCL8 derived peptide and heparin (Figure S2).  
 
Binding of CXCL8 C-terminal Peptides to GAG-Heparin 
            To assess the GAG-binding ability of synthesised C-terminal peptides, SPR binding 
studies were performed. We first evaluated the binding of CXCL8 to a heparin-coated chip 
following established protocols 68. Then, binding of each synthesised peptide was studied, in 
order to evaluate affinity for heparin. Heparin-CXCL8 SPR confirmed binding 68, 69 as shown 
in Figure 2. Peptide binding was only detectable at much higher concentrations of peptide 1 
and 3 (10mM), >104-fold higher than with full length CXCL8 (Sensorgram with magnified y-
axis of binding of peptides 1 and 3 is in Supporting Information (Figure S3)). The E70K 
peptide (Peptide 2) (charge +4), showed significant binding at lower concentrations (5mM) 
than the other peptides (charge +2), but this was still a much higher concentration than full 
length CXCL8 (Figure 2).  
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CXCL8 C-terminal Peptides do not Interfere with GPCR-mediated Signaling  
            The peptides were predicted to bind endothelial GAGs. In order to determine whether 
the peptides also had a role in GPCR-binding, all three peptides were evaluated by CXCL8-
diffusion gradient chemotaxis and CXCL8-mediated calcium signaling. The peptides had no 
significant effect on CXCL8-diffusion gradient chemotaxis (Figure 3). Data on CXCL8-
mediated neutrophil calcium signaling was consistent with the diffusion gradient chemotaxis. 
Neutrophil calcium increased in response to CXCL8 stimulation, but no change was seen 
with the peptides alone. The combination of CXCL8 with each of synthesised peptides did 
not affect calcium flux compared with CXCL8 alone (Figure 4). Thus, data suggested that the 
peptides do not interfere with chemokine-GPCR binding.  
 
C-Terminal Peptides Inhibit Neutrophil Flow-Based Adhesion to Endothelial Cells 
            A schematic representation of the endothelial biochip seeding, and subsequent 
leukocyte flow-based adhesion is shown in Figure 5. Primary neutrophil adhesion in response 
to TNF stimulated, CXCL8 treated HUVECs was used as positive control. Cytokine-
mediated neutrophil flow-based adhesion was reduced in the presence of 50nM of all 3 
peptides (WT peptide and scrambled peptide P<0.01; E70K peptide P<0.001). Similarity 
between the peptides suggest that short positively charged peptides, all containing Lys and 
Arg residues, interfere non-specifically or with functional redundancy with chemokine-
activated neutrophil adhesion to the endothelium under physiological flow conditions (Figure 
5).  
            Further studies performed with the low molecular weight heparin (LMWH) tinzaparin 
showed significant chemokine displacement and inhibition of flow-based chemokine-
mediated neutrophil adhesion (p<0.0001).  
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            In addition, studies using the CXCR1/2 chemokine receptor antagonists repertaxin, 
SB225002 or SB265610 led to significant inhibition of GPCR-chemokine binding as shown 
by significantly reduced neutrophil flow-based adhesion (p<0.0001).  
 
E70K Peptide Inhibits Neutrophil Transendothelial Migration  
            To further investigate CXCL8 C-terminal peptide binding to endothelial GAG, their 
potential to block CXCL8-mediated transendothelial neutrophil migration was evaluated. 
There was no significant effect of Peptide 1 or Peptide 3 on neutrophil transendothelial 
chemotaxis. Peptide 2, E70K reduced CXCL8-mediated neutrophil transendothelial migration 
(p<0.001) (Figure 6) (Figure S4). Primary neutrophils express several cell surface proteins 
involved in endothelial adhesion, in addition to high levels of the CXCL8 receptors, CXCR1 
and CXCR2 (Figure S5). This may partly explain why CXCL8-displacing peptides do not 
fully inhibit neutrophil migration. To determine whether blocking the function of other 
proteins involved in transendothelial migration would further interfere in the process, we 
combined the E70K peptide with an ICAM-1 blocking monoclonal antibody. As  previously 
described blocking ICAM-1 alone did not affect neutrophil transendothelial migration 70. 
When ICAM-1 blockade was combined with E70K there was a significant reduction in 
neutrophil endothelial transmigration, however, this was not greater that E70K alone, 
suggesting no synergistic interaction (Figure 7). This proposes the therapeutic potential of 
E70K peptide to modulate chemokine function by interfering with chemokine GAG binding 
potentially interfering with the formation of the chemokine gradient. 
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Discussion 
            Targeting chemokine GPCR binding has been clinically approved for two indications. 
However, there are numerous examples in pre-clinical studies that suggest they have great 
potential to modify inflammatory response during disease 22-24, 71. The regulation of 
chemokine function by GAG binding using chemokine peptides in vivo has previously been 
investigated 9, 41, 72, but its translational potential has not been fully explored. Here, in order to 
better understand the regulation of chemokine function by GAG binding, chemokine-derived 
peptides were synthesised. All peptides showed low-affinity but significant GAG binding, in 
a charge-dependent manner presumably via electrostatic interactions. Chemotaxis and 
calcium signaling studies confirmed that peptides lacked GPCR antagonist function. The C-
terminal peptides showed a significant reduction in flow-based neutrophil adhesion; however, 
no difference was observed between the peptides. This suggests that integrin-mediated 
neutrophil-endothelial adhesion, which is stimulated by cytokines, can be modulated by all 
the positively-charged peptides tested under physiological flow rate. GAG binding of these 
peptides may not require a defined 3D structure. Neutrophil transendothelial chemotaxis 
assays showed that only Peptide 2, with its higher positive charge, significantly reduced 
neutrophil migration. Peptide 2 has a charge of +4, which is higher than the WT peptide 
(peptide 1) or scrambled peptide (peptide 3) (charge +2). We propose that the higher charge 
increases the affinity for GAG binding, and this contributes to chemokine displacement from 
cell surface GAGs disrupting the chemokine gradient (Figure 8). 
            Alternative approaches to enhance the peptide-GAG binding to increase its ability to 
displace chemokine could include further substitution of positively charged residues in the 
CXCL8 GAG binding region; study of potential folding of unfolded states of the truncated 
chemokine region; or the development of cyclic peptides 73, 74; or stapled peptides to stabilize 
an α-helical structure 75. Furthermore, the inclusion of non-standard amino acids is another 
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strategy to increase the peptide stability against proteolytic cleavage 76. Also, it might be of 
interest to study potential peptide oligomerization, as it could further increase GAG binding 
29, 42, 43, 77, 78. These strategies might facilitate the impairment of the chemokine-mediated 
neutrophil recruitment to ameliorate the injury associated with neutrophil-mediated 
inflammation, such as in IRI during transplantation, or in rheumatoid arthritis 79. 
            Mice express only CXCL8 homologues, KC and MIP-2. Human CXCL8 C-terminal 
peptide used (54-72aa) shares 32% identity and 21% identity with murine homologs (within 
KC/CXCL1 & MIP-2/CXCL2), respectively 80. This makes targeting C-terminal domain 
function in mouse models more difficult. In order to study the potential role of E70K peptide 
in vivo, a murine air pouch model of inflammation was used as optimised earlier by our group 
81, 82. However, no significant effect was observed (data not shown), which may reflect the 
degree of sequence difference described above; or it might have inhibitory effect only in a 
specific environment. Alternative animal models such as humanized mouse model 83 or 
additional physiological studies could further probe the translational role of peptides. 
            Moreover, analysis of the effect of CXCL8-derived peptides on other factors such as 
N-formyl-L-methionyl-L-leucyl-phenylalanine (f-MLP), leukotriene B4 (LTB4), C5a 84; 
immunochemically related chemokines e.g. neutrophil chemoattractant CXCL1, or CXCL9; 
and on other GAGs, may unravel further functionality of synthetic peptides. It is also worth 
noting that chemokine peptides are usually associated with favourable properties such as low 
toxicity and low immunogenicity which contributes to their increasing recognition as 
potential candidates for novel drugs 85, 86. 
            Taken together, this approach shows the ability of CXCL8 (54-72) to bind GAG, and 
to significantly reduce the chemokine-mediated neutrophil adhesion. In addition, the E70K 
CXCL8 peptide also showed a significant reduction in neutrophil transendothelial migration. 
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This might be due to E70K’s higher positive charge and higher binding affinity for 
polyanionic GAG. The ability of chemokine peptides to bind GAG and regulate chemokine 
function requires further work to determine if they have the potential to ameliorate acute or 
chronic neutrophil-driven organ damage. 
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Legends 
Figure 1. A) CXCL8 active sequence. B) Schematic representation of the chemokine binding 
to the endothelial GAG and to the leukocyte chemokine GPCR.  
A) Sequence of the most common active CXCL8 form (aa 28-99), with 72 aa. Green: GAG-
binding residues. Purple: GPCR receptor-binding residues. Red: residues involved in both 
GAG- and receptor-binding. Underlined amino acids: C-terminal α-helix region selected for 
chemical synthesis. B) Schematic representation of chemokine (PDB ID 1IL8/CXCL8) 
interaction with endothelial surface through GAG (residues involved highlighted in orange), 
which enables subsequent high-affinity chemokine binding to leukocyte CXCR1/2 GPCR 
receptor (PDB ID 2LNL) (also highlighted in orange). Chemokine monomer is shown in blue 
and the dimer is depicted with one molecule in blue and the other in red. Note that illustration 
shows one potential scenario of chemokine binding. 
 
Figure 2. Surface Plasmon Resonance of CXCL8 peptide-heparin binding. 
A) SPR sensorgram shows heparin-CXCL8 binding in the range of (50-1000) nM CXCL8, 
and heparin-CXCL8 peptide binding in the range of (2.5-10000) µM peptide. Chemokine or 
peptide were flowed at 5 L/min over the chip. B) Binding shown for each chemokine or 
peptide concentration. Sensorgram with magnified y-axis of binding of WT peptide, and 
scrambled peptide is in Supporting Information (Figure S3). Data were analysed by one-way 
ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. *P<0.05, ***P<0.001. Data is 
representative of three independent experiments over a single heparin-coated SA chip. 
 
Figure 3. Diffusion gradient migration in response to CXCL8 combined with each peptide.  
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10nM CXCL8 were used (positive control). Synthesised CXCL8 C-terminal peptides (10, 
100) nM showed no interference with neutrophil migration in absence of endothelial GAG 
surface, which suggests no binding to CXCR1/2 receptors. WT /Peptide 1 
(KENWVQRVVEKFLKRAENS); E70K /Peptide 2 (KENWVQRVVEKFLKRAKNS); or 
scrambled /Peptide 3 (KVREKNEKWFVEQRVALNS) were studied. Index of migrated cells 
or chemotaxis index (CI) is the ratio between the total number of migrated neutrophils and 
the number of neutrophils that migrated nonspecifically and was calculated for each 
treatment. Data were analysed by one-way ANOVA (P < 0.0001) followed by Bonferroni 
post-hoc test. ***P < 0.001 shows significant migration in response to CXCL8 compared to 
negative control. ns: no significant. Representative data of three independent experiments 
(n=3), each performed in triplicate. 
 
Figure 4. Calcium flux in response to CXCL8 combined with each peptide. 
Intracellular calcium ([Ca2+] i) was measured in response to CXCL8, or CXCL8 combined 
with each peptide (WT/Peptide 1: KENWVQRVVEKFLKRAENS; E70K/Peptide 2: 
KENWVQRVVEKFLKRAKNS; or scrambled/Peptide 3: KVREKNEKWFVEQRVALNS). 
Primary blood neutrophils were labelled with Indo-1, AM. Then, cells were analysed in 
response to HBSS only (negative control), 10nM CXCL8 (positive control) or CXCL8 
combined with each peptide at 50nM, within range of (10-100) nM.  Data was analysed by 
one-way ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. **P <0.01 shows 
significant calcium flux in response to CXCL8 compared to the negative control. ns: no 
significant. Data is representative of three independent experiments (n=3).  
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Figure 5. Schematic representation of leukocyte perfusion and adhesion over primary 
HUVECs.  
A) A. First, HUVEC endothelial cells were seeded over the fibronectin-coated biochip. B. 
Next, leukocytes were loaded onto the endothelial layered chip and initially perfused at high 
flow rate, -10 dynes/cm2 for 10 seconds, to allow leukocyte circulation over the chip 
(negative flow, towards pump). C. Leukocyte adhesion was then analysed at more 
physiological flow rate, -0.5 dynes/cm2 for 3 minutes. Leukocytes were fluorescently 
labelled using 1µM (DIOC6)3.  
B) Flow-based adhesion of primary neutrophils in presence of different modulators. Negative 
control is untreated HUVECs (fibronectin only). Positive control is TNF-stimulated HUVECs 
with 20nM CXCL8 (100µg/mL fibronectin, 1ng/mL TNF/TNF-α). CXCL8 (20nM) and 
CXCL8 peptide (50nM) were added over TNF-stimulated HUVECs and neutrophil adhesion 
was analysed after 1hour treatment. HUVECs were treated with LMWH tinzaparin at 50nM 
for 1hour before performing the assay. Neutrophils were treated with each CXCR1&2 
antagonist (Repertaxin (R); or SB225002 (S1)) or CXCR2 antagonist (SB265610) (S2) at 
50nM for 1hour before the assay. Adherence ratio, obtained from the average of 5 fields of 
view (FOV) per channel of chip, is the ratio between the total number of adhered neutrophils 
and the number of neutrophils that adhered nonspecifically. WT/Peptide 1 (P1) is 
KENWVQRVVEKFLKRAENS; E70K/Peptide 2 (P2) is KENWVQRVVEKFLKRAKNS; 
scrambled/Peptide 3 (P3) is KVREKNEKWFVEQRVALNS. Data was analysed by one-way 
ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. **P <0.01, ***P < 0.001, ****P 
< 0.0001. Representative data of three independent experiments (n=3). 
 
Figure 6. Neutrophil transendothelial migration directed by CXCL8 combined with peptide.  
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Neutrophil response to CXCL8 (10nM), or to CXCL8 combined with each peptide, at (1-
1000) nM (WT/Peptide 1: KENWVQRVVEKFLKRAENS; E70K/Peptide 2: 
KENWVQRVVEKFLKRAKNS; or scrambled/Peptide 3: KVREKNEKWFVEQRVALNS) 
was measured. Cell counts were performed using counting beads by flow cytometry. Index of 
migrated cells or chemotaxis index (CI) is the ratio between the total number of migrated 
neutrophils and the number of neutrophils that migrated nonspecifically. Further titration of 
peptides is shown in Supporting Information (Figure S4). Data were analysed by one-way 
ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. ***P < 0.001 on black column 
indicates significant migration in response to CXCL8 compared to negative control. Data is 
representative of two independent experiments (n=2) from different primary neutrophil 
preparations, each performed in triplicate. 
 
Figure 7. Neutrophil transendothelial migration directed by CXCL8 can be inhibited by E70K 
peptide. Similar effect was shown when peptide was combined with ICAM-1 blocking 
antibody. 
Neutrophil response to CXCL8 (10nM), or to CXCL8 combined with each peptide, at 50nM 
(WT/Peptide 1: KENWVQRVVEKFLKRAENS; E70K/Peptide 2: 
KENWVQRVVEKFLKRAKNS; or scrambled/Peptide 3: KVREKNEKWFVEQRVALNS) 
was measured. Human Microvascular Endothelial Cells (HMECs) were treated with ICAM-1 
blocking antibody. Cell counting was performed using a counting chamber. Index of migrated 
cells or chemotaxis index (CI) is the ratio between the total number of migrated neutrophils 
and the number of neutrophils that migrated nonspecifically. Data were analysed by one-way 
ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. **P < 0.01. ***P < 0.001. ***, 
black column indicates significant migration in response to CXCL8 compared to negative 
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control. Data is representative of three independent experiments (n=3) from different primary 
neutrophil preparations, each performed in duplicate. 
 
Figure 8. The proposed modulatory activity of E70K CXCL8 peptide in in vitro models of 
neutrophil flow-based adhesion and migration during inflammation. 
This model proposes the therapeutic potential of E70K peptide to modulate chemokine 
function by displacing chemokine from cell surface GAG potentially interfering with the 
formation of the chemokine gradient. 
 
 
 
Sup. Figure  1. Schematic representation of chemistry for WT CXCL8 C-terminal peptide. 
A) MALDI of crude peptide produced by SPPS, B) Fractions separation by HPLC, peaks 1-6, 
C) MALDI-TOF of fractions of the pure peptide (from HLPC, peak 2) and D) Analytical 
HPLC chromatogram confirming percentage of purity. 
  
Sup. Figure  2. Circular Dichroism of each peptide alone or combined with heparin.  
CD spectrum of WT CXCL8/IL8 peptide (black), E70K CXCL8/IL8 peptide (dark grey) and 
scrambled peptide (light grey) (25µM peptide), and structure of each peptide in presence of 
50µM heparin (dashed lines). Extended or non-helical structural state of CXCL8 peptides 
shows minor change in presence of heparin, as opposed to the scrambled. Representative data 
of three independent experiments (n=3). 
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Sup. Figure  3. Surface Plasmon Resonance of heparin-CXCL8 peptide at 5 µL/min. 
A) SPR sensorgram of heparin-CXCL8 peptide binding with magnified y-axis for WT 
CXCL8 peptide showed no significant binding at different concentrations as opposed to B) 
E70K CXCL8 peptide. C) Magnified y-axis for scrambled peptide. Data is representative of 
three independent experiments over a single heparin-coated SA chip. 
 
Sup. Figure  4. Neutrophil transendothelial migration directed by CXCL8 combined with 
peptide (extended).  
Neutrophil response to CXCL8 (10nM), or to CXCL8 combined with each peptide, at (0.1-
10000) nM (WT/Peptide 1: KENWVQRVVEKFLKRAENS; E70K/Peptide 2: 
KENWVQRVVEKFLKRAKNS; or scrambled/Peptide 3: KVREKNEKWFVEQRVALNS) 
was measured. Cells counts were performed using counting beads by flow cytometry. Index 
of migrated cells or chemotaxis index (CI) is the ratio between the total number of migrated 
neutrophils and the number of neutrophils that migrated nonspecifically. Data were analysed 
by one-way ANOVA (P < 0.0001) followed by Bonferroni post-hoc test. ***P < 0.001 on 
black column indicates significant migration in response to CXCL8 compared to negative 
control. Data is representative of two independent experiments (n=2) from different primary 
neutrophil preparations, each performed in triplicate. 
 
Sup. Figure  5. Cell surface expression of neutrophil antigens. 
Primary Neutrophils were analysed for cell surface expression of A) chemokine receptors 
CXCR1 and CXCR2 (blue spectrum and orange spectrum, respectively, in the graph), B) 
CD45, and C) adhesion molecule CD11b and D) CD66b by flow cytometry, in relation to 
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their respective isotype controls (red spectra). Median fluorescence intensity (MFI) is 
representative of two independent experiments (n=2). 
 
 
 
 
 
 
 
 
 
 
 
PEPTIDE 
 
CHEMOKINE REGION 
 
YIELD a 
 
PURITY b 
WT (PEPTIDE 1) WT C-terminal 60.4% approx. 95% 
E70K (PEPTIDE 2) E70K C-terminal 10.4% approx. 95% 
Scrambled (PEPTIDE 3) Scrambled from C-terminal 12.7% approx. 95% 
 
Table 1. Summary of yield and purity obtained for each synthesised peptide.  
a) Yield is calculated comparing the dry mass of pure peptide to the mass of crude peptide 
(theoretical mass at 100% yield based on the 0.1mmol resin (0.1mmol peptide) = 
100%peptide = x mg peptide)). b) Purity is obtained from analytical HPLC.  
